Sally L. George
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Sally L. George has a total of 414 co-authors. Here are the top co-authors by number of shared publications:
- Louis Chesler
Institute of Cancer Research, Sutton, United Kingdom
100 shared publications - Deborah A. Tweddle
Wolfson Childhood Cancer Research Centre, Northern Institute for Cancer Research, Newcastle University, Newcastle upon Tyne, United Kingdom
90 shared publications - John Ciaran Hutchinson
Great Ormond Street Hospital NHS Foundation Trust, London, UK
89 shared publications - Michael Hubank
Royal Marsden Hospital, London, United Kingdom
53 shared publications - Darren Hargrave
UCL Great Ormond Street Institute of Child Health, University College London, London, UK
51 shared publications - Lynley V. Marshall
Children & Young People's Unit, The Royal Marsden NHS Foundation Trust, London, United Kingdom
51 shared publications
Latest Publications
- Open Access
Pheno-MYCN maps the morphological footprint of MYCN amplification in paediatric neuroblastoma
MYCN amplification and segmental chromosomal abnormalities have long been prognostic markers in paediatric neuroblastoma, and are often accompanied by morphological changes that portend high-risk disease. Yet quantitative morphological assessment is limited to countable features, such as the mitosis-karyorrhexis index. Other high-risk features, such as nuclear size, pleomorphism and anaplasia, lack formal criteria. This leaves a gap: current simple pathology metrics cannot capture, or localise, the full morphological landscape of high-risk biology, such as disease driven by MYCN. Seeking high-risk cases that standard criteria may miss, we developed Pheno-MYCN, a weakly supervised framework linking slide-level MYCN prediction on 189 H&E whole-slide images to interpretable phenotypic sub-populations that expert review mapped to neuroblastoma morphologies. The aim is not a stronger classifier, but to reveal the morphological basis of MYCN prediction. Cell-level profiling found MYCN-associated differences across sub-populations. Amplified tumour was densely cellular but disorganised, with less connected networks, lower cellular diversity and greater abundance of haemorrhagic and acellular necrotic regions. MYCN-amplified-like tissue was identifiable per slide from these features alone (AUC 0.93-1.00, leave-one-slide-out) and traced as a continuous gradient within tumours. Thus MYCN amplification leaves a concrete, interpretable footprint, readable and localisable on routine H&E.
Open AccessPheno-MYCN maps the morphological footprint of MYCN amplification in paediatric neuroblastoma
MYCN amplification and segmental chromosomal abnormalities have long been prognostic markers in paediatric neuroblastoma, and are often accompanied by morphological changes that portend high-risk disease. Yet quantitative morphological assessment is limited to countable features, such as the mitosis-karyorrhexis index. Other high-risk features, such as nuclear size, pleomorphism and anaplasia, lack formal criteria. This leaves a gap: current simple pathology metrics cannot capture, or localise, the full morphological landscape of high-risk biology, such as disease driven by MYCN. Seeking high-risk cases that standard criteria may miss, we developed Pheno-MYCN, a weakly supervised framework linking slide-level MYCN prediction on 189 H&E whole-slide images to interpretable phenotypic sub-populations that expert review mapped to neuroblastoma morphologies. The aim is not a stronger classifier, but to reveal the morphological basis of MYCN prediction. Cell-level profiling found MYCN-associated differences across sub-populations. Amplified tumour was densely cellular but disorganised, with less connected networks, lower cellular diversity and greater abundance of haemorrhagic and acellular necrotic regions. MYCN-amplified-like tissue was identifiable per slide from these features alone (AUC 0.93-1.00, leave-one-slide-out) and traced as a continuous gradient within tumours. Thus MYCN amplification leaves a concrete, interpretable footprint, readable and localisable on routine H&E.
- Open Access
- 1 July 2026
- Published by American Society of Clinical Oncology (ASCO) in JCO Precision Oncology
- Vol. 10 (7) , e2600045
Frequency and Prognostic Significance of Genetic Abnormalities in a Subgroup of Patients With Intermediate-Risk Neuroblastoma: A SIOPEN Study
PURPOSE: Intermediate-risk neuroblastoma patients older than 18 months, with non– MYCN amplified, International Neuroblastoma Risk Group Staging System localized, unresectable or International Neuroblastoma Staging System stage 3 tumors, and unfavorable histology have inferior outcomes compared with other intermediate-risk patients. This study aimed to identify genetic prognostic biomarkers within this rare subgroup. METHODS: We conducted a large, international study including chromosomal copy number in all cases, next-generation DNA sequencing in most, and telomere maintenance mechanisms and gene expression in a subset, and correlated results with patient survival. RESULTS: Among 98 tumors, 9/98 (9.2%) had oncogene amplifications ( CDK4/MDM2/TERT coamplification (n = 1), CDK4/MDM2 coamplification (n = 4), CDK4 (n = 2), TERT (n = 1), and MYC (n = 1)), while 63/98 (64.3%) had typical segmental chromosomal aberrations (tSCAs). Patients with tumors with oncogene amplification had the worst 5-year event-free survival (EFS; 0%; P < .0001 log-rank test) and 5-year overall survival (OS; 44.4% [95% CI, 21.4 to 92.3]; P < .01 log-rank test). Patients with tumors harboring tSCAs had inferior EFS compared with those with numerical chromosomal aberrations only (51.7% [95% CI, 40.6 to 65.8] v 93.3% [95% CI, 81.5 to 100]; P < .01). Patients with p53 pathway tumor alterations (n = 10) had worse EFS than those without (0% v 61.1% [95% CI, 50.3 to 74.3]; P < .0001, log-rank test) and worse OS (26.7% [95% CI, 8.9 to 80.3] v 80.9% [95% CI, 71.8 to 91.3]; P < .001 log-rank test). Multivariable analysis identified tSCAs as an independent prognostic variable for EFS and oncogene amplification or p53 pathway abnormalities as independent prognostic variables for EFS and OS. CONCLUSION: Oncogene amplification and/or p53 pathway abnormalities and/or typical SCAs identify patients with intermediate-risk neuroblastoma with inferior outcome for whom intensified or alternative treatments should be considered.
- 1 July 2026
- Published by American Society of Clinical Oncology (ASCO) in JCO Precision Oncology
- Vol. 10 (7) , e2600045
Open AccessFrequency and Prognostic Significance of Genetic Abnormalities in a Subgroup of Patients With Intermediate-Risk Neuroblastoma: A SIOPEN Study
PURPOSE: Intermediate-risk neuroblastoma patients older than 18 months, with non– MYCN amplified, International Neuroblastoma Risk Group Staging System localized, unresectable or International Neuroblastoma Staging System stage 3 tumors, and unfavorable histology have inferior outcomes compared with other intermediate-risk patients. This study aimed to identify genetic prognostic biomarkers within this rare subgroup. METHODS: We conducted a large, international study including chromosomal copy number in all cases, next-generation DNA sequencing in most, and telomere maintenance mechanisms and gene expression in a subset, and correlated results with patient survival. RESULTS: Among 98 tumors, 9/98 (9.2%) had oncogene amplifications ( CDK4/MDM2/TERT coamplification (n = 1), CDK4/MDM2 coamplification (n = 4), CDK4 (n = 2), TERT (n = 1), and MYC (n = 1)), while 63/98 (64.3%) had typical segmental chromosomal aberrations (tSCAs). Patients with tumors with oncogene amplification had the worst 5-year event-free survival (EFS; 0%; P < .0001 log-rank test) and 5-year overall survival (OS; 44.4% [95% CI, 21.4 to 92.3]; P < .01 log-rank test). Patients with tumors harboring tSCAs had inferior EFS compared with those with numerical chromosomal aberrations only (51.7% [95% CI, 40.6 to 65.8] v 93.3% [95% CI, 81.5 to 100]; P < .01). Patients with p53 pathway tumor alterations (n = 10) had worse EFS than those without (0% v 61.1% [95% CI, 50.3 to 74.3]; P < .0001, log-rank test) and worse OS (26.7% [95% CI, 8.9 to 80.3] v 80.9% [95% CI, 71.8 to 91.3]; P < .001 log-rank test). Multivariable analysis identified tSCAs as an independent prognostic variable for EFS and oncogene amplification or p53 pathway abnormalities as independent prognostic variables for EFS and OS. CONCLUSION: Oncogene amplification and/or p53 pathway abnormalities and/or typical SCAs identify patients with intermediate-risk neuroblastoma with inferior outcome for whom intensified or alternative treatments should be considered.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S7 from Stratified Medicine Pediatrics: Cell-Free DNA and Serial Tumor Sequencing Identifies Subtype-Specific Cancer Evolution and Epigenetic States
Disease-specific cfDNA vs. tissue sequence variants.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S7 from Stratified Medicine Pediatrics: Cell-Free DNA and Serial Tumor Sequencing Identifies Subtype-Specific Cancer Evolution and Epigenetic States
Disease-specific cfDNA vs. tissue sequence variants.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table 9 from Stratified Medicine Pediatrics: Cell-Free DNA and Serial Tumor Sequencing Identifies Subtype-Specific Cancer Evolution and Epigenetic States
Paediatric cancer specific cfDNA panel (ctPC Panel).
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 9 from Stratified Medicine Pediatrics: Cell-Free DNA and Serial Tumor Sequencing Identifies Subtype-Specific Cancer Evolution and Epigenetic States
Paediatric cancer specific cfDNA panel (ctPC Panel).
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S2 from Stratified Medicine Pediatrics: Cell-Free DNA and Serial Tumor Sequencing Identifies Subtype-Specific Cancer Evolution and Epigenetic States
Disease-specific diagnostic vs. relapse sequence variants.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S2 from Stratified Medicine Pediatrics: Cell-Free DNA and Serial Tumor Sequencing Identifies Subtype-Specific Cancer Evolution and Epigenetic States
Disease-specific diagnostic vs. relapse sequence variants.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table 2 from Stratified Medicine Pediatrics: Cell-Free DNA and Serial Tumor Sequencing Identifies Subtype-Specific Cancer Evolution and Epigenetic States
Relapse vs. primary somatic variants.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 2 from Stratified Medicine Pediatrics: Cell-Free DNA and Serial Tumor Sequencing Identifies Subtype-Specific Cancer Evolution and Epigenetic States
Relapse vs. primary somatic variants.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S10 from Stratified Medicine Pediatrics: Cell-Free DNA and Serial Tumor Sequencing Identifies Subtype-Specific Cancer Evolution and Epigenetic States
Similarity matrix for TFBS sets.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S10 from Stratified Medicine Pediatrics: Cell-Free DNA and Serial Tumor Sequencing Identifies Subtype-Specific Cancer Evolution and Epigenetic States
Similarity matrix for TFBS sets.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S4 from Stratified Medicine Pediatrics: Cell-Free DNA and Serial Tumor Sequencing Identifies Subtype-Specific Cancer Evolution and Epigenetic States
Top relapse-specific copy number events.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S4 from Stratified Medicine Pediatrics: Cell-Free DNA and Serial Tumor Sequencing Identifies Subtype-Specific Cancer Evolution and Epigenetic States
Top relapse-specific copy number events.